Eden Research sees meaningful U.S. sales from 2027 onwards

PUBT · 1d ago
Eden Research sees meaningful U.S. sales from 2027 onwards
  • Eden Research outlined milestones for the financial year to March 31, 2027, including full European approval of Ecovelex in 2026.
  • Emergency-use applications for Ecovelex targeted for Q3 2026, with commercial agreement(s) for its insecticide planned in 2026.
  • Regulatory authorization in Colombia targeted for 2026, with Mevalone launch expected in Q4 2026 via a registration-distribution deal.
  • Meaningful US sales expected from 2027 onward, following EPA approval in September 2022 and California authorization in January 2024.
  • Outlook follows revenue of GBP 4.9 million, operating loss of GBP 2.9 million, cash of GBP 1.5 million at March 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eden Research plc published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.